BACKGROUND: Common genetic variants in the Toll-like receptor 4 (TLR4), which is involved in inflammation and immune response pathways, may be important for prostate cancer. METHODS: In a large nested case-control study of prostate cancer in the Physicians' Health Study (1982-2004), 10 single nucleotide polymorphisms (SNPs) were selected and genotyped to capture common variation within the TLR4 gene as well as 5 kb up and downstream. Unconditional logistic regression was used to assess associations of these SNPs with total prostate cancer incidence, and with prostate cancers defined as advanced stage/lethal (T3/T4, M1/N1(T1-T4), lethal) or high Gleason grade (7 (4 + 3) or greater). Cox-proportional hazards regression was used to assess progression to metastases and death among prostate cancer cases. RESULTS: The study included 1,267 controls and 1,286 incident prostate cancer cases, including 248 advanced stage/lethal and 306 high grade cases. During a median follow-up of 10.6 years, 183 men died of prostate cancer or developed distant metastases. No statistically significant associations between the TLR4 SNPs were found for total prostate cancer incidence, including SNPs for which an association was reported in other published studies. Additionally, there were no significant associations with TLR4 SNPS and the incidence of advanced stage/lethal, or high grade cancers; nor was there evidence among prostate cancer cases for associations of TLR4 SNPs with progression to prostate cancer specific mortality or bony metastases. CONCLUSIONS: Results from this prospective nested case-control study suggest that genetic variation across TLR4 alone is not strongly associated with prostate cancer risk or mortality.
BACKGROUND: Common genetic variants in the Toll-like receptor 4 (TLR4), which is involved in inflammation and immune response pathways, may be important for prostate cancer. METHODS: In a large nested case-control study of prostate cancer in the Physicians' Health Study (1982-2004), 10 single nucleotide polymorphisms (SNPs) were selected and genotyped to capture common variation within the TLR4 gene as well as 5 kb up and downstream. Unconditional logistic regression was used to assess associations of these SNPs with total prostate cancer incidence, and with prostate cancers defined as advanced stage/lethal (T3/T4, M1/N1(T1-T4), lethal) or high Gleason grade (7 (4 + 3) or greater). Cox-proportional hazards regression was used to assess progression to metastases and death among prostate cancer cases. RESULTS: The study included 1,267 controls and 1,286 incident prostate cancer cases, including 248 advanced stage/lethal and 306 high grade cases. During a median follow-up of 10.6 years, 183 men died of prostate cancer or developed distant metastases. No statistically significant associations between the TLR4 SNPs were found for total prostate cancer incidence, including SNPs for which an association was reported in other published studies. Additionally, there were no significant associations with TLR4 SNPS and the incidence of advanced stage/lethal, or high grade cancers; nor was there evidence among prostate cancer cases for associations of TLR4 SNPs with progression to prostate cancer specific mortality or bony metastases. CONCLUSIONS: Results from this prospective nested case-control study suggest that genetic variation across TLR4 alone is not strongly associated with prostate cancer risk or mortality.
Authors: Sara Lindström; David J Hunter; Henrik Grönberg; Pär Stattin; Fredrik Wiklund; Jianfeng Xu; Stephen J Chanock; Richard Hayes; Peter Kraft Journal: Cancer Epidemiol Biomarkers Prev Date: 2010-03-03 Impact factor: 4.254
Authors: Yen-Ching Chen; Edward Giovannucci; Ross Lazarus; Peter Kraft; Shamika Ketkar; David J Hunter Journal: Cancer Res Date: 2005-12-15 Impact factor: 12.701
Authors: Ganesh S Palapattu; Siobhan Sutcliffe; Patrick J Bastian; Elizabeth A Platz; Angelo M De Marzo; William B Isaacs; William G Nelson Journal: Carcinogenesis Date: 2004-10-21 Impact factor: 4.944
Authors: Gerardo Gatti; Amado A Quintar; Virginia Andreani; Juan P Nicola; Cristina A Maldonado; Ana Maria Masini-Repiso; Virginia E Rivero; Mariana Maccioni Journal: Prostate Date: 2009-09-15 Impact factor: 4.104
Authors: Jennifer R Stark; Fredrik Wiklund; Henrik Grönberg; Fredrick Schumacher; Jennifer A Sinnott; Meir J Stampfer; Lorelei A Mucci; Peter Kraft Journal: Cancer Epidemiol Biomarkers Prev Date: 2009-06 Impact factor: 4.254
Authors: Yen Ching Chen; Yi Ling Huang; Elizabeth A Platz; John F Alderete; Lu Zheng; Jennifer R Rider; Peter Kraft; Edward Giovannucci; Siobhan Sutcliffe Journal: Cancer Causes Control Date: 2012-11-21 Impact factor: 2.506
Authors: Pei-Hsuan Weng; Yi-Ling Huang; John H Page; Jen-Hau Chen; Jianfeng Xu; Stella Koutros; Sonja Berndt; Stephen Chanock; Meredith Yeager; John S Witte; Rosalind A Eeles; Douglas F Easton; David E Neal; Jenny Donovan; Freddie C Hamdy; Kenneth R Muir; Graham Giles; Gianluca Severi; Jeffrey R Smith; Carmela R Balistreri; Irene M Shui; Yen-Ching Chen Journal: PLoS One Date: 2014-10-31 Impact factor: 3.240